Transforming growth factor-β signal transduction in epithelial cells

Pharmacology and Therapeutics

Volumn 91, Issue 1, 2001, Pages 1-34

  Yue, Jianbo ^a   Mulder, Kathleen M ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Cancer; Cell cycle; MAPK; Ras; Signal transduction; Smad; TGF

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLINE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PROTEIN; PROTEIN MAD; PROTEIN SMA; RAS PROTEIN; SMAD PROTEIN; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; UNCLASSIFIED DRUG;

BREAST CARCINOMA; CANCER INHIBITION; CANCER THERAPY; CELL CYCLE; CELL GROWTH; CELL INVASION; CELL TYPE; COLON CARCINOMA; ENDOTHELIUM CELL; EPITHELIUM CELL; GROWTH INHIBITION; HEMATOPOIETIC CELL; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; TUMOR CELL; TUMOR GROWTH;

ANIMALS; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; CAENORHABDITIS ELEGANS PROTEINS; DNA-BINDING PROTEINS; EPITHELIAL CELLS; HELMINTH PROTEINS; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRANSFORMING GROWTH FACTOR BETA;

EID: 0035156083     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(01)00143-7     Document Type: Review

References (405)

1. Clues to the pathogenesis of familial colorectal cancer
2. P38 mitogen activated protein kinase can be involved in transforming growth factor β superfamily signal transduction in Drosophila wing morphogenesis
3. Induction of inhibitory Smad6 and Smad7 mRNA by TGF-beta family members
4. Kips off to Myc: Implications for TGF-β signaling
5. p21Cip1/Waf1/SDI1 is elevated through a p53-independent pathway by mimosine
6. Altered metabolic and adhesive properties and increased tumorigenesis associated with increase expression of transforming growth factor β1
7. TGF-β1 inhibits NF-KB/Rel activity inducing apoptosis of B cells: Transcriptional activation of IkB alpha
8. Growth stimulation of human breast cancer cells with anti-transforming growth factor β antibodies: Evidence for negative autocrine regulation by transforming growth factor β
9. Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory response
10. Evidence for a role of Rho-like GTPases and stress-activated protein kinase/c-Jun N-terminal kinase SAPK in transforming growth factor β-mediated signaling
11. Novel activin receptors: Distinct genes and alternative mRNA splicing generate a repertoire of serine/threonine kinase receptors
12. Identification of human activin and TGF-β type I receptors that form heteromeric kinase complexes with type II receptors
13. Activation of signaling by the activin receptor complex
14. TGF-beta1 inhibits NF-kappaB activity through induction of IkappaB alpha expression in human salivary gland cells: A possible mechanism of growth suppression by TGF-beta1
15. A novel member of the transmembrane serine/threonine kinase receptor family is specifically expressed in the gonads and in mesenchymal cells adjacent to the mullerian duct
16. Smad6 as a transcriptional corepressor
17. A soluble transforming growth factor β type III receptor suppresses tumorigenicity and metastasis of human breast cancer MDA-MB 231 cells
18. Transforming growth factor-beta1 modulates p107 function in myeloid cells: Correlation with cell cycle progression
19. Redox-mediated activation of latent transforming growth factorβ1
20. Transforming growth factor-beta activation in irradiated murine mammary gland
21. One systemic administration of transforming growth factor beta 1 reverses age- or glucocorticoid-impaired wound healing
22. Steps in integrin β1-chain glycosylation mediated by TGF-β1 signaling through Ras
23. Transcriptional regulation of the transforming factor beta 1 promoter by v-src gene products is mediated through the AP-1 complex
24. A mechanism of suppression of TGF-β/Smad signaling by NF-kB/RelA
25. Cleavage of the BMP4 antagonist chordin by zebrafish tolliod
26. TGF-β1 regulates gene expression of its own converting enzyme furin
27. Transforming growth factor beta in tissue fibrosis
28. Biology of TGF-β in knockout and transgenic mouse models
29. Purification and properties of extracellular signal-regulated kinase 1, an insulin stimulated microtubule-associated protein 2 kinase
30. ERKs: A family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF
31. A novel SMAD4 gene mutation in seminoma germ cell tumors
32. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer
33. Requirement of type III TGF-β receptor for endocardial cell transformation in the heart
34. MEKK-1, a component of the stress stress-activated protein kinase/c-Jun N-terminal kinase pathway, can selectively activate Smad2-mediated transcriptional activation in endothelial cells
35. Characterization and relationship of Dpp receptors encoded by the saxophone and thick veins genes in Drosophila
36. The Smad5 gene is involved in the intracellular signaling pathways that mediate the inhibitory effects of transforming growth factor-beta on human hematopoiesis
37. Epidermal growth factor induces phosphorylation of extracellular signal-regulated kinase 2 via multiple pathways
38. Parallel signal processing among mammalian MAPKs
39. Type I receptors specify growth inhibitory and transcriptional responses to transforming growth factor beta and activin
40. Disruption of transforming growth factor β signaling by a mutation that prevents transphosphorylation within the receptor complex
41. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: Prognostic implications in primary breast cancer
42. Increased transforming growth factor-β expression inhibits cell proliferation in vitro, yet increases tumorigenicity and tumor growth of Meth A sarcoma cells
43. Molecular cloning, expression, and characterization of the human mitogen-activated protein kinase p44Erk1
44. Endoglin is a component of the transforming growth factor-β receptor system in human endothelial cells
45. Homoneric interactions between the type II TGF-β receptors
46. A transcriptional partner for MAD proteins in TGF-β signaling
47. Smad4 and FAST-1 in the assembly of activin-responsive factor
48. Smad1 recognition and activation by the ALK1 group of transforming growth factor-β family receptors
49. Mechanism of TGF-β receptor inhibition by FKBP12
50. Determinants of specificity in TGF-β signaling transduction
51. Transforming growth factor β1 rescues serum deprivation-induced apoptosis via the mitogen-activated protein kinase MAPK pathway in macrophages
52. An AP-1 binding sequence is essential for regulation of the human a2 I collagen COL1A2 activity by transforming growth factor β
53. New insights into the tumor suppression function of p27Kip1
54. fra-1: A serum-inducible, cellular immediate-early gene that encodes a Fos-related antigen
55. The product of a fos-related gene, fra-1, binds cooperatively to the AP-1 site with Jun: Transcription factor AP-1 is comprised of multiple protein complexes
56. Restored expression of transforming growth factor β type II receptor in k-ras-transformed thyroid cells, TGF-β-resistant, reverts their malignant phenotype
57. Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma
58. A putative protein kinase overcomes pheromone-induced arrest of cell signaling in S. cerevisiae
59. Thrombospondin-1 is a major activator of TGF-β1 in vivo
60. TGF-β1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice
61. Isolation and characterization of the c-fos rat cDNA and analysis of post translational modification in vitro
62. Glial cell specific mechanisms of TGF-β1 induction by IL-1 in cerebral cortex
63. Transforming growth factor β induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism
64. Targeted disruption of Smad3 reveals an essential role in transforming growth factor β-mediated signal transduction
65. Signal transduction by the c-Jun N-terminal kinase
66. Smad2 transduces common signals from receptor serine-threonine and tyrosine kinases
67. Direct binding of Smad3 and Smad4 to critical TGF-β-inducible elements in the promoter of human plasminogen activator inhibitor type 1 gene
68. A protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain
69. TGF-β receptor signaling
70. Smads: Transcriptional activators of TGF-β responses
71. Cloning, expression, and alternative splicing of the receptor for anti-Mullerian hormone
72. Early-onset multifocal inflammation in the transforming growth factor β1-null mouse is lymphocyte mediated
73. Mullerian inhibiting substance in reproduction and cancer
74. Microtubule binding to Smads may regulate TGF-beta activity
75. Transforming growth factor β1 induces interleukin-6 expression via activating protein-1 consisting of JunD homodimers in primary human lung fibroblasts
76. WAF1, a potential mediator of p53 tumor suppression
77. WAF1/CIP1 is induced in p53 mediated G1 arrest and apoptosis
78. FUS3 encode a cdc2+/CDC28 related kinase required for the transition from mitosis into conjugation
79. Interdependent Smad and JNK signaling in transforming growth factor-β-mediated transcription
80. MADR2 maps to 18q21 and encodes a TGF-beta-regulated MAD-related protein that is functionally mutated in colorectal carcinoma
81. Microsatellite instability in inherited and sporadic neoplasms
82. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer
83. The daf-4 gene encodes a bone morphogenetic protein receptor controlling C. elegans dauer larva development
84. TGF-β inhibition of Cdk4 synthesis is linked to cell cycle arrest
85. Differential effects of transforming growth factor beta on the synthesis of Th1- and Th2-like lymphokines by human T lymphocytes
86. Mutant isoforms of the anti-Mullerian hormone type II receptor are not expressed at the cell membrane
87. Ligand-independent activation of TGF-β signaling pathways by heteromeric cytoplasmic domains of TGF-β receptors
88. A kinase subdomain of transforming growth factor-β TGF-β type I receptor determines the TGF-β intracellular signaling specificity
89. Transforming growth factor-β TGF-β-induced downregulation of cyclin A expression requires a functional TGF-β receptor complex. Characterization of chimeric and truncated type I and type II receptors
90. The tumor suppressor Smad4/DPC4 and transcriptional adaptor CBP/p300 are coactivators for Smad3 in TGF-β-induced transcriptional activation
91. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27Kip1-deficient mice
92. The murine gene p27Kip1 is haplo-insufficient for tumor suppression
93. Overexpression of H-ra oncogene induces resistance to the growth-inhibitory action of transforming growth factor beta-1 TGF-β1 and alters the number and type of TGF-β1 receptors in rat intestinal epithelial cell clones
94. Virus induction of osteosarcoma in mice
95. Activation of latent transforming growth factor β
96. TGF-β mediated G1 arrest in a human melanoma cell line lacking p15INK4B: Evidence for cooperation between p21Cip1 and p27Kip1
97. Protein expression of the cell-cycle inhibitor p27Kip1 in malignant melanoma: Inverse correlation with disease-free survival
98. Transcription factor AP-1, and the role of Fra-2
99. Xenopus chordin and Drosophila short gastrulation genes encode homologous proteins functioning in dorsal-ventral axis formation
100. Cloning of a TGF-β type I receptor that forms a heteromeric complex with the TGF-β type II receptor
101. TGF-β regulation of mitogen-activated protein kinases in human breast cancer cells
102. Involvement of extracellular signal-regulated kinase 2 and stress-activated protein kinase/Jun N terminal kinase activation by transforming growth factor β in the negative growth control of breast cancer cells
103. Activins and the receptor serine kinase superfamily
104. A role for Smad6 in development and homeostasis of the cardiovascular system
105. Missense mutations of the transforming growth factor beta type II receptor in human head and neck squamous carcinoma cells
106. Transforming growth factor β effects on expression of G1 cyclins and cyclin-dependent protein kinases
107. daf-1, a C. elegans gene controlling dauer larva development, encodes a novel receptor protein kinase
108. Homeodomain and winged-helix transcription factors recruit activated Smads to distinct promoter elements via a common Smad interaction motif
109. Identification of substrate recognition determinants for human erk1 and erk2 protein kinases
110. Transforming growth factor β3, glial cell line-derived neurotrophic factor, and fibroblast growth factor-2, act in different manners to promote motoneuron survival in vitro
111. Activation of transforming growth factor-beta is inhibited in transgenic apoliproprotein mice
112. Release and activation of platelet latent TGF-β in blood clots during dissolution with plasmin
113. Transforming growth factor-β1 acts as an autocrine-negative growth regulator in colon enterocytic differentiation but not in goblet cell maturation
114. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1
115. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cell
116. Transforming growth factor-β1 TGF-β1 and TGF-β2 decrease expression of CD36, the type B scavenger receptor, through mitogen-activated protein kinase phosphorylation of peroxisome proliferator-activated receptor-γ
117. Involvement of the p38 mitogen-activated protein kinase pathway in transforming growth factor-β-induced gene expression
118. p15Ink4B is a potential effector of cell cycle arrest mediated by TGF-β
119. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin dependent kinases
120. Transforming growth factor β activation of p44mapk in proliferating cultures of epithelial cells
121. Transforming growth factor-β signaling in epithelial cells
122. Altered transforming growth factor β signaling in epithelial cells when Ras activation is blocked
123. Smad6 inhibits BMP/Smad1 signaling by specifically competing with the Smad4 tumor suppressor
124. OAZ uses distinct DNA- and protein-binding zinc fingers in separate BMP-Smad and Olf signaling pathways
125. The MAD-related protein Smad7 associates with TGF-β receptor and functions as an antagonist of TGF-β signaling
126. TGF-β1 activates MAP kinase in human mesangial cells: A possible role in collagen expression
127. TGF-β signaling from cell membrane to nucleus through SMAD proteins
128. Translational control of p27Kip1 accumulation during the cell cycle
129. The types II and III transforming growth factor-β receptors form homo-oligomers
130. MAP kinase pathways in yeast: For mating and more
131. Postgastrulation Smad2-deficient embryos show defects in embryo turning and anterior morphogenesis
132. Transforming growth factor β1: Three-dimensional structure in solution and comparison with the X-ray structure of transforming growth factor β2
133. Characterization of JunD: A new member of the Jun protooncogene family
134. Mechanisms of TGF-β-induced cell cycle arrest
135. TGF-β induces fibronectin synthesis through a c-Jun N-terminal kinase-dependent. Smad4-independent pathway
136. Bone morphogenetic proteins: Multifunctional regulators of vertebrate development
137. Activation of a Ca2+-inhibitable protein kinase that phosphorylates microtubule-associated protein 2 in vitro by growth factors, phorbol esters, and serum in quiescent cultured human fibroblasts
138. The Xenopus dorsalizing factor Gremlin identifies a novel family of secreted proteins that antagonize BMP activities
139. The MEK pathway is required for stimulation of p21Cip1 by transforming growth factor-β
140. Synergistic cooperation of TEF3 and Smad proteins in TGF-β-induced transcription of the plasminogen activator inhibitor-1 gene
141. Altered responsiveness of rat liver epithelial cells to transforming growth factor beta 1 following their transforming with v-raf
142. Crystal structure of the cytoplasmic domain of the type I TGF-β receptor in complex with FKBP12
143. Repression of the CDK activator Cdc25A and cell-cycle arrest by cytokine TGF-β in cells lacking the CDK inhibitor p15
144. E2F and histone deacetylase mediate transforming growth factor β repression of cdc25A during keratinocyte cell cycle arrest
145. Direct binding of follistatin to a complex of bone-morphogenetic protein and its receptor inhibits ventral and epidermal cell fates in early Xenopus embryo
146. Insensitivity to anti-Müllerian hormone due to a mutation in the human anti-Müllerian hormone receptor
147. Differential inhibition of Smad6 and Smad7 on bone morphogenetic protein- and activin mediated growth arrest and apoptosis in B cells
148. TGF-β-stimulated cooperation of Smad proteins with the coactivators CBP/p300
149. Mutations in the activin receptor like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2
150. Identification and functional characterization of a Smad binding element SBE in the JunB promoter that acts as a transforming growth factor-β, activin, and bone morphogenetic protein-inducible enhancer
151. Reduced levels of the cell-cycle inhibitor p27Kip1 in epithelial dysplasia and carcinoma of the oral cavity
152. Acidic cellular environments: Activation of latent TGF-β and sensitization of cellular response to TGF-β and EGF
153. Abnormal lung development and cleft palate in mice lacking TGF-β3 indicated defects of epithelial mesenchymal interaction
154. Transcriptional repression of the transforming growth factor-beta type I receptor gene by DNA methylation results in the development of TGF-β resistance in human gastric cancer
155. Rapid induction of p21Waf1 but delayed down-regulation of Cdc25A in the TGF-β-induced cell cycle arrest of gastric carcinoma cells
156. c-Jun transactivates the promoter of the human p21Cip1/Waf1 gene by acting as a superactivator of the ubiquitous transcription factor Sp1
157. Interaction of the transforming growth factor-beta type I receptor with farnesyl-protein transferase-alpha
158. Genetic change in transforming growth factor beta (TGF-beta) receptor type I gene correlates with insensitivity to TGF-beta 1 in human prostate cancer cells
159. Drosophila Mad binds to DNA and directly mediated activation of vestigial by decapentaplegic
160. Characterization of the promoter region of the human transforming growth factor-β1 gene
161. Promoter sequences of the human transforming growth factor-β1 gene responsive to transforming growth factor-β1 autoinduction
162. Autoinduction of transforming growth factor β1 is mediated by the AP-1 complex
163. The TGF-β superfamily: New members, new receptors, and new genetic tests of function in different organisms
164. Ras- and mitogen-activated protein kinase-dependent and -independent pathways in p21Cip1/Waf1 induction by fibroblast growth factor-2, platelet-derived growth factor, and transforming growth factor β1
165. Ras induces p21Cip1/Waf1 cyclin kinase inhibitor transcriptionally through Sp1-binding sites
166. Enhanced growth of mice lacking the cyclin? dependent kinase inhibitor function of p27(Kip1)
167. A dominant inhibitory mutant of the type II transforming growth factor beta receptor in the malignant progression of a cutaneous T-cell lymphoma
168. Anti-Mullerian hormone Bruxelles: A nonsense mutation associated with the persistent Mullerian duct syndrome
169. Characterization and cloning of a receptor for BMP-2 and BMP-4 from NIH 3T3 cells
170. Opposing BMP and EGF signaling pathways converge on the TGF-β family mediator Smad1
171. A mechanism of repression of TGF-β/Smad signaling by oncogenic Ras
172. Transforming growth factor β1 null mutation in mice causes excessive inflammatory response and early death
173. The oncoprotein Evi-1 represses TGF-β signaling by inhibiting Smad3
174. Characterization of a bone morphogenetic protein responsive Smad-binding element
175. Making the connection: Coupling of stress-activated ERK/MAPK (extracellular-signal-regulated kinase/mitogen-activated protein kinase) core signaling modules to extracellular stimuli and biological responses
176. The stress-activated protein kinase subfamily of c-Jun kinases
177. New functional activities for the p21 family of CDK inhibitors
178. Smad2 and Smad3 positively and negatively regulate TGF beta-dependent transcription through the forkhead DNA-binding protein FAST2
179. Structural and functional characterization of the transforming growth factor β3 promoter
180. Sequence specific protein binding to and activation of the TGF-β3 promoter through a repeated TCCC motif
181. The type II TGF-β receptor autophosphorylates not only on serine and threonine but also on tyrosine residues
182. Cloning of p57Kip2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution
183. Growth factors induce nuclear translocation of MAP kinases (p42MAPK and p44MAPK) but not their activator MAP kinase kinase (p54MAPKK) in fibroblast
184. Drosophila Dpp signaling is mediated by the punt gene product: A dual ligand-binding type II receptor of the TGF-beta receptor family
185. Regulation of immune responses by TGF-β
186. A molecular pathway determining left-right asymmetry in chick embryogenesis
187. Transforming growth factor beta stimulates the human immunodeficiency virus 1 enhancer and requires NF-kappaB activity
188. Expression cloning of the TGF-β type II receptor, a functional transmembrane serine/theronine kinase receptor
189. A glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons
190. Interferon-γ, interleukin-4 and transforming growth factor-β mRNA expression in multiple sclerosis and myasthenia gravis
191. Human type II receptor for bone morphogenic proteins (BMPs): Extension of the two-kinase receptor model to the BMPs
192. Transforming growth factor β signaling through Smad1 in human breast cancer cells
193. Aberrant p27kip1 expression in endocrine and other tumors
194. Ubiquitin-dependent degradation of TGF-β activated Smad2
195. The L3 loop: A structure motif determining specific interactions between Smad proteins and TGF-β receptors
196. Loss of transforming growth factor β1 (TGF-β1)-induced growth arrest and p34cdc2 regulation in ras-transfected epithelial cells
197. Structure and expression of the membrane proteoglycan betaglycan, a component of the TGF-β receptor system
198. Betaglycan presents ligand to the TGF-β signaling receptor
199. Betaglycan can act as a dual modulator of TGF-β access to signaling receptors: Mapping of ligand binding and GAG attachment sites
200. Signaling by chimeric erythropoietin-TGF-β receptors: homodimerization of the cytoplasmic domain of the type I TGF-β receptor and heterodimerization with the type II receptor are both required for intracellular signaling transduction
201. Positive and negative regulation of type II TGF-β receptor signal transduction by autophosphorylation on multiple serine residues
202. The Ski oncoprotein interacts with the Smad proteins to repress TGF-β signaling
203. Specific activation of Smad1 signaling pathways by the BMP7 type I receptor, ALK2
204. Avian sarcoma virus 17 carries the Jun oncogene
205. Inactivation of p27Kip1 by the viral E1A oncoprotein in TGF-β-treated cells
206. Sensitivity to transforming growth factor β1 induced growth arrest is common in human squamous cell carcinoma cell lines: c-myc down-regulation and p21Waf1 induction are important early events
207. Tumor suppressor activity of the TGF-β pathway in human cancers
208. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability
209. Signaling from TPA to MAP kinase requires protein kinase C, raf and MEK: Reconstitution of the signaling pathway in vitro
210. Transforming growth factor beta 1 is a potent survival factor for rat embryo motoneurons in culture
211. TGF-β signal transduction
212. Identification of two Smad4 proteins in Xenopus
213. Follistatins and a 2-macroglobulin are soluble binding proteins for inhibin and activin
214. Characterization of type II activin receptors. Binding, processing and phosphorylation
215. Cloning of a second type of activin receptor and functional characterization in Xenopus embryos
216. p57Kip2, a structurally distinct member of the p21Cip1 cdk inhibitor family, is a candidate tumor suppressor gene
217. Cell specific induction of distinct oncogenes of the Jun family is responsible for differential regulation of collagenase gene expression by transforming growth factor-β in fibroblasts and keratinocytes
218. Endoglin, a TGF-β binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1
219. Mouse lefty2 and zebrafish activin are feedback inhibitors of nodal signaling during vertebrate gastrulation
220. Human cytomegalovirus infection induces transcription and secretion of transforming growth factor beta1
221. Induction of WAF1/CIP1 by a p53-independent pathways
222. The crystal structure of TGF-beta 3 and comparison to TGF-beta 2: Implications for receptor binding
223. Role for carbohydrate structures in TGF-β1 latency
224. Transforming growth factor-β1 levels are elevated in the striatum and in ventricular cerebrospinal fluid in Parkinson's disease
225. Principles of CDK regulation
226. The transforming growth factor receptors types I, II and III form hetero-oligomeric complexes in the presence of ligand
227. Extracellular signal regulated kinase and the small GTP-binding protein, Rac, contribute to the effects of transforming growth factor-β1 on gene expression
228. Role of Ras and MAPKs in TGF-β signaling
229. Alterations in c-myc expression in relation to maturational status of human colon carcinoma cells
230. Growth factor expression and response in human colon carcinoma cells
231. Activation of p21ras by transforming growth factor β in epithelial cells
232. Modulation of c-myc by transforming growth factor-beta in human colon carcinoma cells
233. Evidence for c-myc in the signaling pathway for TGF-beta in well-differentiated human colon carcinoma cells
234. Inhibitory effects of transforming growth factor beta 1 on mitogenic response, transforming growth factor alpha, and c-myc in quiescent, well-differentiated colon carcinoma cells
235. Role of receptor complexes in resistance or sensitivity to growth inhibition by TGF-β in intestinal epithelial cell clones
236. Transforming growth factor beta 1 regulation of c-myc expression, pRB phosphorylation, and cell cycle progression in keratinocytes
237. Interaction between growth factors and integrins: Latent forms of transforming growth factor-β are ligands for the integrin aVβ1
238. The integrin aVβ6 binds and activates latent TGF-β1: A mechanism for regulating pulmonary inflammation and fibrosis
239. Fra-2-positive autoregulatory loop triggered by mitogen-activated protein kinase (MAPK) and Fra-2 phosphorylation sites by MAPK
240. A transforming growth factor beta receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability
241. Transforming growth factor β targeted inactivation of cyclin E: Cyclin-dependent kinase 2 (Cdk2) complexes by inhibition of Cdk2 activating kinase activity
242. Identification of Smad7, a TGF-β-inducible antagonist of TGF-β signaling
243. Synergistic signaling in fetal brain by STAT3-Smad1 complex bridged by p300
244. Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors
245. Receptor serine/threonine kinases implicated in the control of Drosophila body pattern by decapentaplegic
246. E1A inhibits transforming growth factor-beta signaling through binding to Smad proteins
247. Isolation and characterization of fra-2, an additional member of the fos gene family
248. Identification of type I and type II serine/threonine kinase receptors for growth/differentiation factor-5
249. Identification of a human type II receptor for bone morphogenetic protein-4 that forms differential heteromeric complexes with bone morphogenetic protein type I receptors
250. Smad2 role in mesoderm formation, left-right patterning and craniofacial development
251. Characterization of latent TGF-β activation by murine peritoneal macrophages
252. TGF-β1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial cells
253. Distinct roles of the intracellular domains of transforming growth factor-β type I and type II receptors in signal transduction
254. Silencing of TGF-beta signaling by the pseudoreceptor BAMBI
255. Identification of an activating transcription factor ATF binding site in the human transforming growth factor β2 promoter
256. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin dependent kinase inhibitor p27
257. Mutation of a mutL homolog in hereditary colon cancer
258. Smad and AML proteins synergistically confer transforming growth factor β1 responsiveness to human germ-line IgA genes
259. Genetic changes in the transforming growth factor beta (TGF-beta) type II receptor gene in human gastric cancer cells: Correlation with sensitivity to growth inhibition by TGF-beta
260. Microsatellite instability and mutations of the transforming growth factor beta type II receptor gene in colorectal cancer
261. Type I transforming growth factor beta receptor maps to 9q22 and exhibits a polymorphism and a rare variant within a polyalanine tract
262. TbetaR-I6A is a candidate tumor susceptibility allele
263. Identification of the regulatory phosphorylation sites in pp42/mitogen-activated protein kinase (MAP kinase)
264. Protein kinase phosphorylation site sequences and consensus specificity motifs: Tabulations
265. Identification of two bone morphogenetic protein type I receptors in Drosophila and evidence that Brk25D is a decapentaplegic receptor
266. Glial transforming growth factor TGF-β isotypes in multiple sclerosis: Differential glial expression of TGF-β1, 2, and 3 isotypes in multiple sclerosis
267. Cyclin D1 and D2 mediate Myc-induced proliferation via sequestration of p27Kip1 and p21Cip1
268. Joining the complex: Cyclin-dependent kinase inhibitory proteins and the cell cycle
269. Characterization of a 60-kDa cell surface-associated transforming growth factor-beta binding protein that can interfere with transforming growth factor-beta receptor binding
270. Specificity, diversity, and regulation in TGF-β superfamily signaling
271. Mammary tumor suppression by transforming growth factor beta 1 transgene expression
272. Transforming growth factor beta 1 suppression of c-myc gene transcription: Role in inhibition of keratinocyte proliferation
273. TGF-beta 1 inhibition of c-myc transcription and growth in keratinocytes is abrogated by viral transforming proteins with pRB binding domains
274. p27Kip1, acyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest
275. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients
276. TGF-β in the central nervous system: Potential roles in ischemic injury and neurodegenerative diseases
277. Transforming growth factor-β3 is required for secondary palate fusion
278. Evidence that Smad2 is a tumor suppressor implicated in the control of cellular invasion
279. Genetic screens to identify elements of the decapentaplegic signaling pathway in Drosophila
280. Jun: Transcription factor and oncoprotein
281. Transforming growth factor-β induces collagenase-3 expression by human gingival fibroblast via p38 mitogen-activated protein kinase
282. Rapid stimulation by insulin of a serine/threonine kinase in 3T3-L1 adipocytes that phosphorylate microtubule-associated protein 2 in vitro
283. Transforming growth factor-beta1 induces activation of Ras, Raf-1, MEK and MAPK in rat hepatic stellate cells
284. The subcellular locations of p15Ink4b and p27Kip1 coordinate their inhibitory interactions with cdk4 and cdk2
285. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-β
286. The activation sequence of thrombospondin-1 interacts with the latency-associated peptide to regulate activation of latent transforming growth factor-β
287. Transforming growth factor-β-mediated p15Ink4B induction and growth inhibition in astrocytes is Smad3-dependent and a pathway prominently altered in human glioma cell lines
288. Mad-related genes in the human
289. Frequency of Smad gene mutations in human cancers
290. Molecular and cell biology of TGF-β
291. The transforming growth factor βs
292. Differential expression of the TGF-β isoforms in embryogenesis suggests specific roles in developing and adult tissue
293. New class of transforming growth factors potentiated by epidermal growth factor: Isolation from nonneoplastic tissue
294. Isolation from murine sarcoma cells of novel transforming growth factors potentiated by EGF
295. Purification and properties of a type β transforming growth factor from bovine kidney
296. An element of the transforming growth factor-beta1 5'-untranslated region represses translation and specifically binds a cytosolic factor
297. Cloning and characterization of a human type II receptor for bone morphogenetic proteins
298. Cyclin-dependent kinase inhibitor p27KIP1 in lymphoid tissue: p27KIP1 expression is inversely proportional to the proliferative index
299. TGF-β2 knockout mice have multiple developmental defects that are non-overlapping with other TGF-β knockout phenotypes
300. ATF-2 is a common nuclear target of Smad and TAK1 pathways in transforming growth factor-β signaling
301. Caenorhabditis elegans genes sma-2, sma-3, and sma-4 define a conserved family of transforming growth factor beta pathway components
302. A deletion in the gene for transforming growth factor beta type I receptor abolishes growth regulation by transforming growth factor beta in a cutaneous T-cell lymphoma
303. An unusual feature revealed by the crystal structure at 2.2A resolution of human transforming growth factor-β2
304. JunB inhibits and c-fos stimulates the transforming and trans-activating activities of c-Jun
305. DPC4 gene in various tumor types
306. Genetic characterization and cloning of mothers against dpp, a gene required for decapentaplegic function in Drosophila melanogaster
307. TGF-beta 1 inhibits branching morphogenesis and N-myc expression in lung bud organ cultures
308. TGF-beta-induced phosphorylation of Smad3 regulates its interaction with coactivator p300/CREB-binding protein
309. Inhibitors of mammalian G1 cyclin dependent kinases
310. CDK inhibitors: Positive and negative regulators of G1-phase progression
311. Smad1 interacts with homeobox DNA-binding proteins in bone morphogenetic protein signaling
312. Crystal structure of a Smad MH1 domain bound to DNA: Insights on DNA binding in TGF-β signaling
313. Role of TAK1 an TAB1 in BMP signaling in early Xenopus development
314. TAB1: An activator of the TAK1 MAPKKK in TGF-β signal transduction
315. Transcriptional activating activity of Smad4: Roles of Smad hetero oligomerization and enhancement by an associating transactivator
316. Identification and characterization of a PDZ protein that interacts with activin type II receptors
317. Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease
318. The tumor suppressor gene Smad4/Dpc4 is required for gastrulation and later for anterior development of the mouse embryo
319. Phosphorylation of Ser165 in TGF-beta type I receptor modulates TGF-beta1-induced cellular responses
320. The inhibitory effects of transforming growth factor beta1 on breast cancer cell proliferation are mediated through regulation of aberrant nuclear factor-kappaB/Rel expression
321. A major advance in the use of growth factors to enhance wound healing
322. A first or dominant immunization. II. Induced immunoglobulin carries transforming growth factor β and suppresses cytolytic T cell responses to unrelated alloantigens
323. Transforming growth factor-β1 overproduction in prostate cancer: Effects on growth in vivo and in vitro
324. Negative feedback regulation of TGF-β signaling by the SnoN oncoprotein
325. Crystal structure of transforming growth factor β2: An unusual fold for the superfamily
326. Expression of transforming growth factor beta type II receptor leads to reduced malignancy in human breast cancer MCF-7 cells
327. Interaction of the Ski oncoprotein with Smad3 regulates TGF-β signaling
328. SnoN and SKI protooncoproteins are rapidly degraded in response to transforming growth factor β signaling
329. Latent transforming growth factor-beta1 associates to fibroblast extracellular matrix via latent TGF-β binding protein
330. Differential expression and cell cycle regulation of the cyclin-dependent kinase 4 inhibitor p16Ink4A
331. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas
332. Transforming growth factor-beta1 is a new form of tumor suppressor with true haploid insufficiency
333. Activin receptor-like kinases: A novel subclass of cell-surface receptors with predicted serine/threonine kinase activity
334. Characterization of type I receptors for transforming growth factor-β an activin
335. Identification of type I receptors for osteogenic protein-1 and bone morphogenetic protein-4
336. Microstatellite instability in cancer of the proximal colon
337. Human chondrodysplasia due to a mutation in a TGF-beta superfamily member
338. CREB binding protein is a required coactivator for Smad-dependent, transforming growth factor β transcriptional responses in endothelial cells
339. p27, a novel inhibitor of G1 cyclin-cdk protein kinase activity, is related to p21
340. Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma
341. Molecular cloning of a novel type I receptor serine/threonine kinase for the TGF-beta superfamily from rat brain
342. SARA, a FYVE domain protein that recruits Smad2 to the TGF-β receptor
343. Induction of the interleukin receptor antagonist protein by transforming growth factor beta
344. Somatic in vivo alterations of the JV18-1 gene at 18q21 in humanlung cancers
345. Inhibition of transforming growth factor-β/Smad signaling by the interferon-v/STAT pathway
346. Transforming growth factor β isoforms in the adult rat central and peripheral nervous system
347. p57Kip2 is degraded through the proteasome in osteoblasts stimulated to proliferation by transforming growth factor β1
348. Differential effects of transforming growth factor β on the expression of collagenase-1 and collagenase-3 in human fibroblasts
349. Transforming growth factor-beta 1 is in plaques in Alzheimer and Down pathologies
350. TGF-β1 and TGF-β2 concentrations are elevated in Parkinson's disease in ventricular cerebrospinal fluid
351. Interaction of transforming growth factor-β receptor I with farnesyl-protein transferase-α in yeast and mammalian cells
352. SIP1, a novel zinc finger/homeodomain repressor, interacts with Smad proteins and binds to 5'-CACCT sequence in candidate target genes
353. Three activator protein-1-binding sites bound by the Fra-2-JunD complex cooperate for the regulation of murine laminin a3A Lama3A promoter activity by transforming growth factor β
354. Homology between the DNA-binding of the GCN4 regulatory protein of yeast and the carboxy terminal region of a protein coded for by the oncogene Jun
355. Transforming growth factor type beta induces monocyte chemotaxis and growth factor production
356. Demonstration that mutation of type II transforming growth factor β receptor inactivates its tumor suppressor activity in replication error-positive colon carcinoma cells
357. Transforming growth factor-beta1 stimulates protein kinase A in mesangial cells
358. The p21Ras farnesyltransferase a subunit in TGF-β and activin signaling
359. The immunophilin FFKBP12 functions as a common inhibitor of the TGF-β family type I transforming growth factor β receptors
360. Expression cloning and characterization of the TGF-β type II receptor
361. Myc down-regulation by transforming growth factor beta required for activation of the p15Ink4b G1 arrest pathway
362. Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways
363. Signaling activity of transforming growth factor β type II receptors lacking specific domains in the cytoplasmic region
364. GS domain mutations that constitutively activate TβRI, the downstream signaling component in the TGF-β receptor complex
365. Transforming growth factor-beta (TGF-beta) is chemotactic for human monocytes and induces their expression of angiogenic activity
366. Smad3-Smad4 and AP-1 complexes synergize in transcriptional activation of the c-Jun promoter by transforming growth factor β
367. A Smad transcriptional corepressor
368. Multiple modes of repression by the Smad transcriptional corepressor TGIF
369. Regulation of Smad activity
370. TGF-β signals through a heteromeric protein kinase receptor complex
371. Mechanism of activation of the TGF-β receptor
372. Structural basis of Smad2 recognition by the Smad anchor for receptor activation
373. TGF-β1 is an autocrine-negative growth regulator of human colon carcinoma FET cells in vivo as revealed by transfection of an antisense expression vector
374. The Drosophila saxophone gene: A serine-threonine kinase receptor of the TGF-beta superfamily
375. Involvement of Ras/Raf/AP-1 in BMP4 signaling during xenopus embryonic development
376. Targeted disruption of the biglycan gene leads to an osteoporosis-like phenotype in mice
377. The MSG1 non-DNA-binding transactivator binds to the p300/CBP coactivators, enhancing their functional link to the Smad transcription factors
378. Identification of a member of the MAPKKK family as a potential mediator of TGF-β signaling transduction
379. XIAP, a cellular member of the inhibitor of the inhibitor of apoptosis protein family, links the receptors to TAB1-TAK1 in the BMP signaling pathway
380. Negative regulation of transforming growth factor-β by the proteoglycan decorin
381. Endoglin forms a heteromeric complex with the signaling receptors for transforming growth factor-β
382. Osteogenic protein-1 binds to activin type II receptors and induces certain activin-like effects
383. Two different signal transduction pathways can be activated by transforming growth factor beta 1 in epithelial cells
384. Convergence of transforming growth factor-β and vitamin D signaling pathways on Smad transcriptional coactivators
385. Identification of an estrogen response element activated by metabolites of 17 beta-estradiol and aloxifene
386. Targeted disruption of Smad3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-β
387. Tumor suppressor Smad4 is a transforming factor β inducible DNA binding protein
388. Regulation of transforming growth factor-beta1 expression by the hepatitis B virus (HBV) X transactivator Role in HBV pathogenesis
389. Requirement of Ras/MAPK pathway activation by transforming growth factor beta for transforming growth factor beta 1 production in a smad-dependent pathway
390. Blockade of TGF-β3 up-regulation of p27Kip1 and p21Cip1 by expression of RasN17 in epithelial cells
391. Cross-talk between the Smad1 and Ras/MEK signaling pathways for TGF-β
392. Cloning and expression of a Rat Smad1: Regulation by TGF-β and modulation by the Ras/MEK pathway
393. Human Smad3 and Smad4 are sequence-specific transcription activators
394. Transforming growth factor beta induces myoblast differentiation in the presence of mitogens
395. The product of a novel growth factor activated gene, FosB, interacts with Jun proteins enhancing their DNA binding activity
396. Active transcriptional repression by the Rb-E2F complex mediates G1 arrest triggered by p16Ink4a TGF-β, and contact inhibition
397. Regulation of Smad signaling by protein associations and signaling crosstalk
398. Smad3 and Smad4 cooperate with c-Jun/c-Fos to mediate TGF-β-induced transcription
399. Clonal heterogeneity of the sensitivity of human colon carcinoma cell lines to TGF-beta isoforms
400. Transforming growth factor beta isoform-specific differences in interactions with type I and II transforming growth factor beta receptors
401. Hematopoietic progenitor kinase 1 is a component of transforming growth factor β-induced c Jun N-terminal kinase signaling cascade
402. Characterization of human FAST-1, a TGF-β and activin signal transducer
403. A Smad ubiquitin ligase targets the BMP pathway and affects embryonic pattern formation
404. Smad3 mutant mice develop metastatic colorectal cancer
405. Smad proteins physically interact with calmodulin